Treatment of patients w/ unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy & radiation therapy. In combination w/ etoposide & either carboplatin or cisplatin, as 1st line treatment of adults w/ extensive-stage small cell lung cancer (ES-SCLC).
Administer as IV infusion over 60 min. Unresectable stage III NSCLC 10 mg/kg every 2 wk until disease progression, unacceptable toxicity, or max of 12 mth. ES-SCLC 1,500 mg in combination w/ chemotherapy every 3 wk (21 days) for 4 cycles, followed by 1,500 mg every 4 wk as single agent until disease progression or unacceptable toxicity. Patient weighing ≤30 kg 20 mg/kg in combination w/ chemotherapy every 3 wk (21 days) for 4 cycles, followed by 20 mg/kg every 4 wk as single agent until wt increases to >30 kg.
W/hold for moderate & permanently discontinue for severe or life-threatening pneumonitis; transaminase or total bilirubin elevation; colitis; nephritis; rash. W/hold for moderate, severe or life-threatening endocrinopathies. W/hold for severe or life-threatening infection. Interrupt or slow infusion rate for mild or moderate & permanently discontinue for severe or life-threatening infusion-related reactions. Monitor for changes in liver &/or renal function. Can cause fetal harm. Females of reproductive potential should use effective contraception. Do not breastfeed during treatment & for at least 3 mth after the last dose.
Most common (≥20%) in unresectable stage III NSCLC: Cough, fatigue, pneumonitis/radiation pneumonitis, upper resp tract infections, dyspnea, rash. Most common (≥20%) in ES-SCLC: Nausea, fatigue/asthenia, alopecia.
L01FF03 - durvalumab ; Belongs to the class of PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors. Used in the treatment of cancer.
Sign Out
